Antiproteinuric Effect of Valsartan and Lisinopril
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00171574|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : February 24, 2017
Title: Antiproteinuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), double blind, parallel group, controlled trial, 5 months follow-up.
Objective: To evaluate the antiproteinuric effect of high doses of valsartan vs combo treatment in no-diabetic and diabetic patients.
Hypothesis: Combo treatment reduces microalbuminuria, proteinuria and the albumin/creatinin ratio more than monotherapies.
Design: Multicentric, randomized, double blind, parallel group, active controlled.
Dose / regimen Valsartan 320 vs Lisinopril 40 vs Valsartan/lisinopril 160/20
|Condition or disease||Intervention/treatment||Phase|
|Hypertension Diabetic Nephropathy||Drug: Valsartan Drug: Valsartan plus HCTZ Drug: Lisinopril||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||124 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up|
|Study Start Date :||November 2004|
|Actual Primary Completion Date :||July 2006|
|Actual Study Completion Date :||July 2006|
- Change from baseline in urine protein excretion after 20 weeks
- Change from baseline in a laboratory measure of kidney function after 20 weeks
- Change from baseline in systolic blood pressure after 20 weeks
- Change from baseline in diastolic blood pressure after 20 weeks
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00171574
|Study Director:||Novartis Pharmaceuticals||Novartis Pharmaceuticals|